Skip to content
Evevident
Original paper
2010NEJMRheumatology/Immunology

RAVE

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

RCTANCA-associated vasculitis

On this page

Overview

Rituximab was noninferior to cyclophosphamide for remission induction in severe ANCA vasculitis.

Clinical takeaway

RAVE shifted ANCA-associated vasculitis induction therapy by validating rituximab as an alternative to cyclophosphamide, especially useful in relapsing disease or fertility/toxicity concerns.

Key result

Complete remission off prednisone at 6 months occurred in 64% with rituximab vs 53% with cyclophosphamide.

Practice impact

Rituximab became a first-line induction option for severe GPA/MPA.

Evidence

Study design

Randomized, double-blind, double-dummy, noninferiority trial.

Enrollment

197

Follow-up

Primary outcome at 6 months.

Geography

United States

Clinical question

Is rituximab noninferior to cyclophosphamide for induction of remission in severe ANCA-associated vasculitis?

Population

  • Patients with severe ANCA-associated vasculitis, including granulomatosis with polyangiitis and microscopic polyangiitis.

Intervention

Rituximab plus glucocorticoids.

Comparator

Cyclophosphamide followed by azathioprine plus glucocorticoids.

Primary outcome

Complete remission at 6 months with prednisone discontinued.

Rituximab was noninferior to cyclophosphamide for remission induction in severe ANCA-associated vasculitis.

Absolute difference / 11 / CI 95% CI -3.2 to 24.3 percentage points / p=<0.001 for noninferiority

Key results

  • Complete remission at 6 months: 64% with rituximab vs 53% with cyclophosphamide.
  • Rituximab met noninferiority criteria and was superior in relapsing disease subgroup.
  • Adverse-event rates were similar overall.

Harms

  • Infusion reactions and infection risk occur with rituximab.
  • Cyclophosphamide toxicity includes infertility, cytopenias, bladder toxicity, infection, and malignancy risk.

Clinical Use

When to cite

  • When choosing rituximab versus cyclophosphamide for ANCA vasculitis induction.

Practice impact

  • Made rituximab a standard induction option for severe ANCA-associated vasculitis.

Applicability

  • Severe GPA/MPA requiring remission induction, especially relapsing disease or situations where cyclophosphamide toxicity is undesirable.

Limitations

  • Small trial compared with cardiology mega-trials.
  • Long-term maintenance choices require additional evidence beyond the 6-month induction endpoint.

Common misinterpretations

  • Noninferiority for induction does not mean no maintenance therapy is needed after remission.

Citation

Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905

Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis.